Histopathology based AI model predicts anti-angiogenic therapy response in renal cancer clinical trial
Abstract Anti-angiogenic (AA) therapy is a cornerstone of metastatic clear cell renal cell carcinoma (ccRCC) treatment, but not everyone responds, and predictive biomarkers are lacking. CD31, a marker of vasculature, is insufficient, and the Angioscore, an RNA-based angiogenesis quantification metho...
Gorde:
| Egile Nagusiak: | , , , , , , , , , , , , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Nature Portfolio
2025-03-01
|
| Saila: | Nature Communications |
| Sarrera elektronikoa: | https://doi.org/10.1038/s41467-025-57717-6 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|